Johnson & Johnson
JNJ
$230.42
+2.75%
Johnson & Johnson is the world's largest and most diverse healthcare firm, operating through two core divisions: Innovative Medicine (pharmaceuticals) and MedTech (medical devices). The company is a dominant market leader with a century-long reputation for stability, having recently completed its transformation into a pure-play healthcare entity following the 2023 divestiture of its consumer business, Kenvue. The current investor narrative is focused on the company's post-restructuring growth trajectory, particularly the performance of its key immunology drug Stelara against biosimilar competition, the successful integration of its new therapeutic focus areas (immunology, oncology, neurology), and navigating the evolving regulatory landscape, including potential drug pricing tariffs.…
JNJ
Johnson & Johnson
$230.42
Related headlines
Investment Opinion: Should I buy JNJ Today?
Rating & Thesis: Hold. JNJ is a high-quality, defensive healthcare giant in a transitional phase; investors should wait for clearer signs of post-Stelara growth re-acceleration before committing new capital, despite its strong fundamentals and reasonable valuation. This aligns with the mixed but generally neutral-to-positive analyst sentiment observed.
Supporting Evidence: The hold rating is supported by four key data points: 1) A reasonable forward PE of 17.9x, below its own recent historical peaks, 2) Solid but decelerating revenue growth of 9.1% YoY in Q4 2025, 3) Exceptional profitability and cash generation, with TTM FCF of $19.70B and a gross margin of 86.4%, and 4) A secure dividend with a 46.2% payout ratio, funded by strong cash flow. The stock's low beta (0.33) further supports its role as a portfolio stabilizer, not a growth driver.
Risks & Conditions: The two biggest risks are a prolonged slowdown in the Innovative Medicine division and negative sentiment from drug pricing regulations. This Hold would upgrade to a Buy if the forward PE compressed below 16x on sustained fears, or if Q2/Q3 2026 earnings demonstrate a clear re-acceleration of organic growth excluding Stelara. It would downgrade to a Sell if revenue growth decelerates below 5% YoY or if net margins contract significantly. Relative to its own history, the stock appears fairly valued; relative to the market, it carries a premium justified by its stability and cash flow.
Sign up to view all
JNJ 12-Month Price Forecast
JNJ presents a classic 'GARP at a reasonable price' scenario with elevated uncertainty. The fundamentals are undeniably strong, with world-class profitability and cash flow, but the near-term growth narrative is clouded by the Stelara transition. The base case of range-bound trading is most likely, as the company's defensive attributes and dividend will put a floor under the stock, while growth concerns will cap upside. The stance would upgrade to bullish on evidence of successful pipeline commercialization in upcoming earnings, or downgrade to bearish on a breakdown below key support at $225 accompanied by deteriorating fundamentals.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Johnson & Johnson's 12-month outlook, with a consensus price target around $299.55 and implied upside of +30.0% versus the current price.
Average Target
$299.55
15 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
15
covering this stock
Price Range
$184 - $300
Analyst target range
The stock is covered by 15 analysts, indicating strong institutional interest. Specific Buy/Hold/Sell distribution and a consensus average target price are not provided in the data, preventing a calculation of implied upside or downside. The provided institutional ratings from early 2026 show a mix of bullish and neutral sentiment, with firms like RBC Capital (Outperform), HSBC (Buy), Citigroup (Buy), and Morgan Stanley (Upgraded to Overweight) expressing positive views, while Barclays and JP Morgan maintain Equal Weight/Neutral ratings. The target price range is also not available in the dataset, so the assumptions behind high and low targets cannot be detailed. The recent ratings actions, including an upgrade from Morgan Stanley, suggest some analysts see value or catalysts emerging. The absence of Sell ratings in the recent sample points to a generally favorable or cautious, but not bearish, analyst stance on the stock.
Bulls vs Bears: JNJ Investment Factors
The evidence currently tilts slightly bullish, grounded in the company's strong fundamentals, cash generation, and a valuation that has become more attractive after a recent pullback. However, the bear case is substantiated by clear signs of growth deceleration and negative near-term price momentum. The single most important tension in the investment debate is the trajectory of the Innovative Medicine division's growth. If new drugs can successfully offset the decline of Stelara and re-accelerate top-line growth, the bullish thesis of a reasonably valued cash cow will prevail. If the Stelara headwind persists and growth continues to slow, the bearish concerns over elevated multiples and dependence on pharma innovation will gain prominence.
Bullish
- Strong Post-Restructuring Growth: Revenue grew 9.1% YoY in Q4 2025 to $24.56B, demonstrating the company's ability to grow as a pure-play healthcare entity. The Innovative Medicine division, at $15.76B, is the clear primary engine for this expansion.
- Exceptional Profitability & Cash Flow: The company generates immense cash, with TTM free cash flow of $19.70B and a robust gross margin of 86.4% in Q4 2025. This funds a secure dividend (46.2% payout ratio), buybacks, and strategic investments without financial strain.
- Attractive Valuation After Pullback: The trailing PE of 18.8x is significantly below recent historical highs (e.g., 36.2x in Q3 2024) and the forward PE is 17.9x. This suggests the recent -6.94% monthly price decline may offer a more reasonable entry point.
- Defensive Profile & Low Volatility: With a beta of 0.33, JNJ is significantly less volatile than the market, a classic defensive characteristic. Its 1-year price change of +47.09% also shows it can deliver strong absolute returns during uptrends.
Bearish
- Revenue Growth Deceleration: Sequential quarterly revenue growth is moderating (Q1-Q4 2025: $21.89B, $23.74B, $23.99B, $24.56B). A key near-term headwind is a steep sales decline for the blockbuster drug Stelara, as noted in recent news.
- Negative Short-Term Momentum: The stock is down -6.94% over the past month and has significantly underperformed the S&P 500 by -16.92% in relative strength. This signals a clear consolidation/profit-taking phase after the strong rally.
- Regulatory & Pricing Risk: Recent news highlights the threat of 100% tariffs on imported drugs for companies without pricing deals. While JNJ may be shielded, this creates sector-wide uncertainty and potential for negative sentiment spillover.
- High Valuation Multiples: While the PE is reasonable historically, other valuation metrics are elevated: Price/Sales is 5.35x and Price/Cash Flow is 20.55x. This leaves little room for error if growth slows further.
JNJ Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +47.09%. However, it is currently trading in a corrective phase, positioned at approximately 90% of its 52-week range ($146.12 to $251.71), indicating it is pulling back from recent highs after a significant rally. This positioning near the top of the range suggests the stock may be consolidating gains or facing resistance after its strong run. Recent momentum has turned sharply negative, with the stock down -6.94% over the past month and essentially flat (-0.03%) over the past three months, a stark deceleration from the longer-term trend. This divergence signals a potential short-term consolidation or profit-taking phase, especially notable given the S&P 500's positive returns over the same periods, resulting in a significant -16.92% relative strength for JNJ over one month. Key technical support is at the 52-week low of $146.12, while immediate resistance is at the 52-week high of $251.71. A breakdown below the recent April lows near $225 could signal a deeper correction, while a breakout above $251.71 would reaffirm the primary bull trend. The stock's low beta of 0.33 indicates it is significantly less volatile than the broader market, which is characteristic of a defensive healthcare giant and suggests smaller price swings on a relative basis.
Beta
0.26
0.26x market volatility
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$146-$252
Price range past year
Annual Return
+55.2%
Cumulative gain past year
| Period | JNJ Return | S&P 500 |
|---|---|---|
| 1m | -3.2% | +8.2% |
| 3m | -5.8% | +9.0% |
| 6m | +17.6% | +10.5% |
| 1y | +55.2% | +26.5% |
| ytd | +11.1% | +8.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
JNJ Fundamental Analysis
Revenue growth remains positive but is showing signs of deceleration on a sequential basis. The most recent Q4 2025 revenue was $24.56 billion, representing a solid 9.1% year-over-year increase. However, examining the quarterly trend from Q1 to Q4 2025 reveals revenue of $21.89B, $23.74B, $23.99B, and $24.56B, indicating growth is moderating. Segment data shows the Innovative Medicine division, at $15.76 billion, is the primary growth driver, significantly larger than the $8.80 billion MedTech segment. The company is highly profitable, with Q4 2025 net income of $5.12 billion and a robust gross margin of 86.4%. Profitability has been strong but variable; for instance, net income in Q1 2025 was an exceptional $11.0 billion (driven by other income), while Q2 and Q3 2025 were $5.54 billion and $5.15 billion, respectively. The trailing twelve-month free cash flow is a substantial $19.70 billion, providing immense financial flexibility. The balance sheet is healthy with a manageable debt-to-equity ratio of 0.59 and a current ratio of 1.03, indicating adequate short-term liquidity. The strong cash generation, evidenced by the high free cash flow, allows the company to comfortably fund its dividend (payout ratio of 46.2%), share repurchases, and strategic investments without relying heavily on external financing.
Quarterly Revenue
$24.6B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$19.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is JNJ Overvalued?
Given the company's consistent profitability, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE ratio is 18.8x, while the forward PE is slightly lower at 17.9x, indicating the market expects modest earnings growth. Compared to sector averages (data not available in the provided set), a precise premium/discount calculation cannot be made, but JNJ's PE in the high-teens is typical for a large-cap, slow-growth pharmaceutical company. Historically, the stock's own valuation provides critical context: the current trailing PE of 18.8x sits well below its historical high observed in recent quarters, such as 36.2x in Q3 2024 and 29.2x in Q1 2024. It is also below the 24.6x seen in Q4 2025. This suggests the stock is trading at a more reasonable valuation within its own historical band, potentially offering a more attractive entry point after the recent price pullback, assuming earnings fundamentals remain intact.
PE
18.8x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -1502x~36x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: JNJ's primary financial risk is revenue concentration and growth deceleration within its larger Innovative Medicine segment, which comprised 64% of Q4 2025 sales. A steep decline in sales for the key drug Stelara, as highlighted in recent news, poses a near-term headwind. While profitability is robust, net income has shown significant quarterly variability, from $11.0B in Q1 2025 to $5.12B in Q4 2025, indicating potential earnings volatility. The company's dependence on continued successful drug innovation to justify its current valuation (PS ratio of 5.35x) is a key operational risk if the pipeline underdelivers.
Market & Competitive Risks: The stock faces valuation compression risk if its growth trajectory moderates further, as it trades at a forward PE of 17.9x and a Price/Cash Flow of 20.55x. Externally, the evolving regulatory landscape, specifically the threat of 100% tariffs on imported drugs for companies without pricing deals, creates sector-wide uncertainty and potential sentiment headwinds. While JNJ's low beta of 0.33 provides defensive characteristics, it also means the stock may lag during strong market rallies, as evidenced by its recent -16.92% relative underperformance versus the S&P 500 over one month.
Worst-Case Scenario: The most damaging scenario would involve a faster-than-expected erosion of Stelara sales combined with pipeline setbacks in immunology/oncology, leading to a guidance cut and multiple compression. This could be exacerbated by a broader sector derating due to aggressive drug pricing policies. In this adverse scenario, the stock could realistically re-test its 52-week low of $146.12, representing a downside of approximately -35.7% from the current price of ~$227. Historical support near $225 has recently broken, suggesting the path to lower levels is technically plausible if fundamentals deteriorate.
FAQ
The key risks are, in order of severity: 1) Product-Specific: Accelerated decline of the blockbuster drug Stelara, creating a near-term revenue headwind (as noted in Q1 2026 news). 2) Regulatory: Evolving drug pricing landscape, including potential tariffs, which could compress sector multiples even for exempt companies like JNJ. 3) Execution: Failure of the new drug pipeline (immunology, oncology, neurology) to offset patent expiries, leading to growth stagnation. 4) Valuation: The stock's premium multiples (e.g., PS 5.35x) leave it vulnerable to derating if growth slows more than expected.
The 12-month forecast presents three scenarios. The Base Case (55% probability) sees the stock trading between $230 and $251.71, assuming stable execution and mid-single-digit growth. The Bull Case (30% probability) targets $251.71 to $270, driven by successful new drug launches and a defensive market rally. The Bear Case (15% probability) could see a retest of support down to $146.12, triggered by steeper Stelara declines and sector-wide selling. The Base Case is most likely, implying limited near-term upside from the current ~$227 price but significant fundamental downside protection.
JNJ appears fairly valued relative to its own history but carries a premium relative to the market, which is justified by its quality. The forward PE of 17.9x is below its recent historical highs (e.g., 36.2x in Q3 2024), suggesting it is not overvalued on that basis. However, its Price/Sales ratio of 5.35x and Price/Cash Flow of 20.55x are not cheap. The valuation implies the market expects steady, mid-single-digit growth and is paying for the company's defensive characteristics and reliable cash flow, not for explosive expansion.
JNJ is a good stock to buy for conservative, income-focused investors with a long-term horizon, but timing is suboptimal for aggressive accumulation. The company's strong fundamentals, including $19.70B in TTM free cash flow and a secure 2.46% dividend yield, provide a solid foundation. However, with the stock in a short-term downtrend (-6.94% over 1 month) and facing a key growth transition with its Stelara drug, new investors may benefit from waiting for clearer signs of stability or a deeper pullback towards the $210-$220 support zone before establishing a full position.
JNJ is unequivocally suitable for long-term investment, not short-term trading. Its low beta (0.33) minimizes volatility, making it a poor candidate for short-term momentum plays, as evidenced by its recent underperformance. The company's century-long history, durable business model, and reliable dividend are hallmarks of a long-term compounder. Investors should have a minimum holding period of 3-5 years to ride out transitional periods like the current Stelara headwind and benefit from the company's cash flow reinvestment and pipeline development.